LACTIN-V is under clinical development by Osel and currently in Phase I for Unspecified Gynecological Disorders. According to GlobalData, Phase I drugs for Unspecified Gynecological Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the LACTIN-V LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LACTIN-V overview
LACTIN-V is under development for the prevention and treatment of recurrent bacterial vaginosis, preterm birth and human papilloma virus, cervical dysplasia and prevent cervical cancer. The therapeutic candidate is administered through vaginal route. The therapeutic candidate contains a single strain of Lactobacillus crispatus, CTV-05 and may aid in the treatment of infections. It was also under development for the treatment of Candida infection (yeast infections).
LACTIN-V was under development for the treatment of recurrent urinary tract infections (rUTI),
Osel overview
Osel is a biotechnology company focused on developing live biotherapeutic products (LBPs). The company’s pipeline products include LACTIN-V which reduces pre-term birth in high risk women, recurrence of bacterial vaginosis and HPV progression and cervical dysplasia, prevents cervical cancer; CBM588 that enhances efficacy of immune checkpoint therapy in cancer; MucoCept Technology Platform which reduces risk of HIV in women; Gassericin K7 Bacteriocin for the treatment of cervical cancer in conjunction with chemoradiation therapy. Its therapeutic areas include gastrointestinal tract microbiome and indications in oncology and immunotherapy. The company collaborates with research institutions. Osel is headquartered in Mountain View, California, the US.
For a complete picture of LACTIN-V’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
